

IN THE CLAIMS:

Please cancel claims 80 to 94 without prejudice, amend the claims and add new claims 104 to 105 as follows:

1. -78. (Cancelled)

79. (Previously Presented) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to an epitope of an antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein CM-1 antibody produced by a cell line deposited as DSM ACC 2584 specifically binds to said epitope of the antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

80.-94. (Cancelled)

95. (Previously Presented) The antibody or functional fragment of claim 79, wherein said antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.

96. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment induces apoptosis of at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

97. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said functional fragment is selected from the group consisting of F<sub>v</sub>, Fab, Fab', and F(ab')<sub>2</sub>.

98. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment is a human antibody.

99. (Previously Presented) The purified antibody of claim 79, wherein said antibody is a monoclonal antibody.

100. (Currently Amended) ~~A purified antibody or antigen binding fragment~~ The purified antibody or functional fragment of claim 79, comprising the amino acid sequence of SEQ ID NO:1.

101. (Currently Amended) ~~A purified antibody or antigen binding fragment~~ The purified antibody or functional fragment of claim 79, comprising the amino acid sequence of SEQ ID NO:3.

102. (Previously Presented) A purified antibody or antigen binding fragment comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3.

103. (Previously Presented) A purified antibody or antigen binding fragment, wherein the antibody is produced by a cell line deposited as DSM ACC 2584.

104. (New) The purified antibody or functional fragment of claim 79, further comprising a pharmaceutically acceptable carrier.

105. (New) A cell that produces the purified antibody or functional fragment of claim 79.